|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/538 | (2006.01) |
| A61K 31/519 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 4161528 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20781202.5 |
| Date of filing the European patent application | 2020-09-14 | |
| (97) | Date of publication of the European application | 2023-04-12 |
| (45) | Date of publication and mention of the grant of the patent | 2025-11-05 |
| (46) | Date of publication of the claims translation | 2026-02-10 |
| (86) | Number | PCT/US2020/050753 |
| Date | 2020-09-14 |
| (87) | Number | WO 2021/247064 |
| Date | 2021-12-09 |
| (30) | Number | Date | Country code |
| 202063034214 P | 2020-06-03 | US |
| (72) |
STUBBS, Matthew , US
LIU, Phillip C. , US
|
| (73) |
Incyte Corporation ,
1801 Augustine Cut-Off, Wilmington, DE 19803,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Ruksolitinibo derinys su INCB057643, skirtas panaudoti mieloproliferacinių navikų gydymui |
| COMBINATION OF RUXOLITINIB WITH INCB057643 FOR USE IN THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS |